文献速递临床试验与 GCP

多中心单盲随机平行组研究评估鼻牙槽塑形治疗非综合征性单侧完全性唇裂牙槽突裂腭裂患者有效性的方案(NAMUC研究):一项随机对照试验的研究方案

A multi-centric, single-blinded, randomized, parallel-group study to evaluate the effectiveness of nasoalveolar moulding treatment in non-syndromic patients with complete unilateral cleft lip, alveolus and palate (NAMUC study): a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-07-04

NAMUC研究是一项研究者发起的多中心、单盲、随机平行组对照试验,计划纳入274例非综合征性单侧完全性唇腭裂患者,比较唇裂术前鼻牙槽塑形(NAM)与不治疗对照的有效性。主要终点为5岁时采用Asher McDade指数评估的鼻唇美学,次要结局包括牙颌面发育、言语、听力、成本效果、生活质量等。

要点

  • NAMUC研究拟纳入274例非综合征性单侧完全性唇腭裂患者,比较术前NAM与不治疗对照。
  • 主要终点为5岁时用Asher McDade指数评估的鼻唇美学。
  • 随机化通过中心在线系统进行,按裂隙宽度、出生体重和试验中心分层。

核心结论

  • 作者预期该研究关于NAM矫治器长期有效性的结果及成本效果评价可消除全球临床照护中的困境与差异。

研究设计与样本

  • NAMUC研究为研究者发起的多中心、单盲、随机平行组对照试验。
  • 研究拟纳入274例非综合征性单侧完全性唇腭裂患者,比较唇裂术前NAM治疗与不治疗对照组。
  • 随机化通过中心在线系统进行,按裂隙宽度、出生体重和临床试验中心分层。

主要发现

  • 主要终点为5岁时采用Asher McDade指数测量的鼻唇美学。
  • 次要结局包括牙颌面发育、言语、听力、成本效果、生活质量、患者感知、喂养和无形获益。

关键数值与推荐

  • 鼻牙槽塑形(NAM)为0至6月龄间进行的非手术治疗,旨在唇裂术前减小裂隙并改善鼻部美学。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出支持NAM技术的证据有限,尚无关于该治疗有效性的高质量长期临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cleft lip and palate (CLP) are among the most common congenital anomaly that affects up to 33,000 newborns in India every year. Nasoalveolar moulding (NAM) is a non-surgical treatment performed between 0 and 6 months of age to reduce the cleft and improve nasal aesthetics prior to lip surgery. The NAM treatment has been a controversial treatment option with 51% of the cleft teams in Europe, 37% of teams in the USA and 25 of cleft teams in India adopting this methodology. This treatment adds to the already existing high burden of care for these patients. Furthermore, the supporting evidence for this technique is limited with no high-quality long-term clinical trials available on the effectiveness of this treatment. METHOD: The NAMUC study is an investigator-initiated, multi-centre, single-blinded randomized controlled trial with a parallel group design. The study will compare the effectiveness of NAM treatment provided prior to lip surgery against the no-treatment control group in 274 patients with non-syndromic unilateral complete cleft lip and palate. The primary endpoint of the trial is the nasolabial aesthetics measured using the Asher McDade index at 5 years of age. The secondary outcomes include dentofacial development, speech, hearing, cost-effectiveness, quality of life, patient perception, feeding and intangible benefits. Randomization will be carried out via central online system and stratified based on cleft width, birth weight and clinical trial site. DISCUSSION: We expect the results from this study on the effectiveness of treatment with NAM appliance in the long term along with the cost-effectiveness evaluation can eliminate the dilemma and differences in clinical care across the globe. TRIAL REGISTRATION: ClinicalTrials.gov CTRI/2022/11/047426 (Clinical Trials Registry India). Registered on 18 November 2022. The first patient was recruited on 11 December 2022. CTR India does not pick up on Google search with just the trial number. The following steps have to be carried out to pick up. How to search: ( https://ctri.nic.in/Clinicaltrials/advsearch.php -use the search boxes by entering the following details: Interventional trial > November 2022 > NAMUC).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Thiruvenkatachari B, Bonanthaya K, Kuijpers Jagtman AM, et al. A multi-centric, single-blinded, randomized, parallel-group study to evaluate the effectiveness of nasoalveolar moulding treatment in non-syndromic patients with complete unilateral cleft lip, alveolus and palate (NAMUC study): a study protocol for a randomized controlled trial. Trials. 2024. PMID: 38965585. doi:10.1186/s13063-024-08229-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。